Fundraising Fox
/Companies
Sign in

Forwardvue Pharma

Mobile, US · Founded 2020 · Alabama corporation · 1 known investors

Find your way into Forwardvue Pharma

Sign up to see every warm intro you have to Forwardvue Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Forwardvue Pharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months. The company operates in ophthalmic drug development.

BiotechHealthtechMedical Devices

Founders & leadership

Forwardvue Pharma was founded in 2020 by Alan Franklin.

AF
Alan FranklinOphthalmologist, Vitreoretinal Diseases and SurgeryDr. Alan Franklin earned a B.S. in Biomedical Engineering from Northwestern University and an M.D. from the Medical College of Ohio/University of Toledo, followed by a Ph.D. from Vanderbilt University in Molecular Physiology and Biophysics focused on pancreatic islet cell gene expression. He completed ophthalmology residency at Saint Louis University, serving as chief resident in 1996–1997, and vitreoretinal fellowship training at University of Iowa Hospitals and Clinics, where he conducted research on anti-vascular agents for diabetic retinopathy and age-related macular degeneration. Dr. Franklin has practiced vitreoretinal surgery and served as principal investigator in multiple clinical trials for retinal diseases while publishing and presenting research on therapeutic candidates and surgical visualization technologies.
RM
RAJ MATURINamed on SEC filing
ND
NEIL DONNENFELDNamed on SEC filing
RT
RUBEN TIMMONSNamed on SEC filing
BB
BARRY BUTLERNamed on SEC filing
AS
AMIR SHOJAEINamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements
▶$1MofferedNov 2022 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • NEIL DONNENFELDDirector
  • ALAN FRANKLINExecutive Officer, Director
  • AMIR SHOJAEIDirector
  • RAJ MATURIDirector
  • RUBEN TIMMONSDirector
  • BOB KATZExecutive Officer, Director
  • BARRY BUTLERDirector
Offering amount
$1M
Minimum investment
$10K
Incorporated
Corporation, Alabama, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MofferedOct 2020 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • RAJ MATURIDirector
  • ALAN FRANKLINExecutive Officer, Director
  • NEIL DONNENFELDDirector
  • RUBEN TIMMONSDirector
  • BARRY BUTLERDirector
  • AMIR SHOJAEIDirector
Offering amount
$4M
Minimum investment
$10K
Proceeds to insiders
$50K
Incorporated
Corporation, Alabama, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Forwardvue Pharma do?
ForwardVue Pharma develops a long-acting ORAI1 blocker administered by intravitreal injection to treat retinal neovascular disease, with a target dosing of 1-2 injections per year for durability up to 12 months. The company operates in ophthalmic drug development.
Who founded Forwardvue Pharma?
Forwardvue Pharma was founded by Alan Franklin in 2020.
Who are Forwardvue Pharma's investors?
Forwardvue Pharma's investors include OphthaFund.
Where is Forwardvue Pharma headquartered?
Forwardvue Pharma is headquartered in Mobile, US.